PentixaPharm is proceeding its development pipeline in lymphoma located in the central nervous system in an advanced diagnostic trial with the PET-based agent PentixaFor as well as an early phase therapeutic trial with the targeted radiotherapy agent PentixaTher.

PentixaFor, a small peptide based [68Ga]Gallium PET imaging agent, addresses specifically the chemokine 4 receptor, expressed by a multitude of malignant diseases in oncological, cardiovascular and  inflammatory indications allowing for personalised molecular imaging with high specificity and sensitivity. 

PentixaTher, the complementary therapeutic agent to PentixaFor, equipped with the high energy beta emitter [90Y]Yttrium targets oncological malignancies via internal peptide receptor radioligand therapy. 

The lead development for PentixaFor and PentixaTher focuses on hematological indications targeting unmet medical needs for patients and offers benefits over existing therapies via a reduced side effect profile. 

PentixaTec, a small peptide based [99mTc]Technetium SPECT imaging agent, allowing for affordable and easy-to-implement chemokine 4 receptor directed imaging in oncological, cardiovascular and inflammatory indications.






Radiopharmaceuticals are drugs which are a combination of a vector, linker and radionuclide, each having a different function. The vector, e.g. a small molecule, peptide or antibody, is intended to specifically bind to a target tissue (target), e.g. a tumor. The more precisely the vector binds to the target and not to non-targeted tissues, organs or cells, the higher the medical benefit reducing side effects. The linker connects the vector to the radioactive payload to be delivered to the disease burden.

Depending on the type of radiation and the energy, radiopharmaceuticals can be used as a diagnostic agent (DX) or as a therapeutic agent (TX). When used as a diagnostic tool, PET (positron emission tomopraphy) or SPECT (single photon emission computed tomography) detect the radioactivity bound to the target tissue and provide visual information about the disease burden. When used as a therapeutic agent, the radiation and energy of the radionuclide (alpha or beta emitters) is used to incude DNA double strand breaks followed by cell death. Whereas the vector is often the same for the diagnostic and therapeutic agent the radionuclide differs in type of radiation and energy. This combination of diagnostic and therapeutic enables the THERANOSTIC approach of FIND, FIGHT and FOLLOW for a specific disease which offers effective personalised patient treatment.

PentixaPharm GmbH

Bismarckstraße 13
97080 Würzburg

Robert-Rössle-Str. 10
13125 Berlin
Mail info@pentixapharm.com